Related Experiment Videos
Molecular lymphatic mapping of the sentinel lymph node.
Bret Taback1, Kahoko Hashimoto, Christine T Kuo
1Department of Molecular Oncology, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, California 90404, USA.
The American Journal of Pathology
|October 9, 2002
Summary
Molecular lymphatic mapping (MLM) uses DNA markers to reliably identify sentinel lymph nodes (SLNs) during cancer surgery. This technique improves accuracy in detecting metastasis and aids retrospective analysis of tissue samples.
Area of Science:
- Oncology
- Molecular Biology
- Surgical Pathology
Background:
- Sentinel lymph node (SLN) identification is crucial for staging cancers like melanoma and breast cancer.
- Current mapping agents (blue dye, radioisotopes) have limitations in quantification and durability.
- Accurate identification of SLNs is vital for precise histopathological assessment and metastasis detection.
Purpose of the Study:
- To develop a durable molecular marker for precise SLN identification.
- To establish a method for quantitative assessment of lymph node hierarchy.
- To enable reliable retrospective analysis of archival lymph node specimens.
Main Methods:
- Development of molecular lymphatic mapping (MLM) using rice gene DNA (rDNA) in a rat model.
- Preoperative injection of rDNA into lymphatic vessels to label SLNs.
- Detection of rDNA in SLNs using polymerase chain reaction (PCR) on frozen and paraffin-embedded tissues.
Main Results:
- MLM successfully and permanently labeled SLNs in a rat model.
- PCR reliably detected injected rDNA (1.25 µg) in labeled SLNs.
- The procedure was validated in a rat breast tumor metastasis model.
Conclusions:
- Molecular lymphatic mapping offers a durable and quantifiable method for SLN identification.
- MLM enhances the accuracy of metastasis detection and retrospective analysis.
- This technique can be combined with conventional mapping agents for comprehensive SLN assessment.